Important short term value creating milestones Below are the main evens for q3 and q4 as per presentation on may 2021: many ppl think reduvo sales in q4 is most important even but IMO QIXLEEF q3 update and ard003 are way more important. If QIXLEEF pass ph ii that drug itself will worth 500 millions us at least. With positive indicators in place I think we have low risk but I think investors are looking for a stronger confirmation to de-risk the investment. We are getting close. Gl longs
Short-Term Value-Creating Milestones
QIXLEEF - PLENITUDE:
Q2: ACCELERATE PATIENT ENROLMENT
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY
QIXLEEF – REBORN1:
Q2: 1ST PATIENT IN
Q3: INTERIM ANALYSIS
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY Q1-22: END OF ENROLMENT
ARDS-003:
Q4: LAST HEALTHY VOLUNTEER Q1-22: LAST PATIENT IN
CAU M Z:
BRIDGE TO QIXLEEF
R ED U VO :
Q4:DIN EXPECTED
ENJOUCA :
MARKET LAUNCH DATES: CANADA Q4 2021, AUSTRALIA Q1 2022, GERMANY Q2 2022